Phosphodiesterase Inhibitors: Types and Purpose - Cleveland Clinic
2022年6月8日 · PDE-4: This type is specific to your lungs, causing muscles in your airway (especially your bronchial tubes) to constrict and tense up. PDE-5: These are in the lungs, and …
List of Selective phosphodiesterase-4 inhibitors - Drugs.com
Selective phosphodiesterase-4 inhibitors are used in the treatment of severe Chronic Obstructive Pulmonary Disease (COPD) to reduce the risk of COPD exacerbations. They are not …
Phosphodiesterase Inhibitors: What Are They - Osmosis
2020年11月24日 · PDE4 inhibitors can be used to treat asthma, chronic obstructive pulmonary disease, psoriasis, atopic dermatitis, inflammatory bowel disease, and rheumatoid arthritis. …
Phosphodiesterase Inhibitors - StatPearls - NCBI Bookshelf
2023年6月26日 · PDE-4 inhibitors decrease pro-inflammatory mediators and cause bronchodilation by inhibiting the degradation of cAMP. Theophylline is a non-specific PDE …
An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022
Since the marketing of Roflumilast, three additional compounds have been marketed as PDE4-inhibitor drugs i.e., Crisaborole (by Pfizer) for atopic dermatitis , Apremilast (by Celgene) for …
How Do PDE4 Inhibitors (DMARDs) Work? - RxList
PDE4 inhibitors are prescribed to reduce inflammation and slow down disease progression in psoriasis, an inflammatory skin condition that can also lead to joint inflammation in many …
Phosphodiesterase-4 Enzyme Inhibitors: Drug Class, Uses, Side ... - RxList
Phosphodiesterase-4 enzyme (PDE-4) inhibitors are medications used to treat chronic obstructive pulmonary disease (COPD). Learn about how they work, usages, side effects, and a list of drugs.
Phosphodiesterase inhibitors - Knowledge @ AMBOSS
Phosphodiesterase (PDE) inhibitors are a heterogenic class of drugs that target various isoforms of PDE enzymes. Normally, the PDE decreases cAMP or cGMP in target cells by catalyzing …
Phosphodiesterase 4 Inhibitors - DrugBank Online
Compounds that specifically inhibit PHOSPHODIESTERASE 4. A selective phosphodiesterase-4 inhibitor indicated to decrease the risk of exacerbations in patients with severe chronic …
Phosphodiesterase‑4 inhibitors: a review of current ... - PubMed
Here, we review the current status of development of PDE4 inhibitors since 2013 and discuss the applicability of novel medicinal-chemistry strategies for identifying more efficient and safer …
- 某些结果已被删除一些您可能无法访问的结果已被隐去。显示无法访问的结果